Kyoichi Nomura

Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

Ludwig Kappos, Amit Bar‐Or, Bruce Cree et al. · The Lancet · 2018 · 925 citations

Medicine, Neurology, Pharmacology +9

Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial

Masayuki Tahara, Tomoko Oeda, Kazumasa Okada et al. · The Lancet Neurology · 2020 · 368 citations

Medicine, Clinical Sciences, Neurology +5

CSF cytokine profile in MOG-IgG+ neurological disease is similar to AQP4-IgG+ NMOSD but distinct from MS: a cross-sectional study and potential therapeutic implications

Kimihiko Kaneko, Douglas Kazutoshi Sato, Ichiro Nakashima et al. · Journal of Neurology Neurosurgery & Psychiatry · 2018 · 199 citations · Full text

Life Sciences, Neurology, Neuroscience +17

Comparing intracerebral hemorrhages associated with direct oral anticoagulants or warfarin

Ryota Kurogi, Kunihiro Nishimura, Michikazu Nakai et al. · Neurology · 2018 · 83 citations · Full text

Medicine, Internal Medicine, Pharmacology +17

Apathy/depression, but not subjective fatigue, is related with cognitive dysfunction in patients with multiple sclerosis

Masaaki Niino, Nobuhiro Mifune, Tatsuo Kohriyama et al. · BMC Neurology · 2014 · 81 citations · Full text

Medicine, Neurology, Psychology +17